Accessibility Menu
Qiagen logo

Qiagen(NYSE) QGEN

Market Cap$9.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)+2,261%
5 Year-17%
1 Year-10%
1 Month+9%
Premium Feature
Moneyball Superscore
69/100
$44.23
-1.49%
-0.67Today
After hours$44.10-$0.13 (-0.31%)
Qiagen last closing stock price
MetricPriceDate
Last closeUSD 44.072026-08-21
Qiagen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.61%USD 42.952026-08-14
1 month+8.63%USD 40.572026-07-22
3 month+26.44%USD 34.862026-05-22
Year to date-1.28%USD 44.642025-12-31
1 year-9.64%USD 48.772025-08-21
3 year+0.8%USD 43.722023-08-22
5 year-16.63%USD 52.862021-08-20
Since inception+2,260.91%USD 1.871996-06-28

Qiagen Financials at a Glance

Market Cap

$9.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.10B

Net Income (TTM)

$409.32M

EPS (TTM)

$1.97

P/E Ratio

22.38

Dividend

$0.35

Beta (Volatility)

0.62 (Low)

Price

$44.23

Volume

846.749

Open

$44.39

Previous Close

$44.07

Daily Range

$43.78 - $44.47

52-Week Range

$32.53 - $57.82

Estimated Earnings Date

Nov 3, 2026

QGEN News

a lab with scientists working on computers and lab equipment

Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More

Luis Sanchez CFAAug 4, 2020
qiagenLogo

Here's How Qiagen Trounced Q1 Estimates

Keith SpeightsMay 7, 2020
Coronavirus blood test

Coronavirus Test-makers Ramp Up Production

Brian Orelli, PhDMar 18, 2020
GettyImages-1089913166

Will COVID-19 Derail New Drugs?

David HaenMar 18, 2020
Coronavirus vial

FDA Warns About Potential Supply Chain Issues for Coronavirus Tests

Keith SpeightsMar 16, 2020
Acquisition deal

Here's Why Qiagen Jumped Higher Today

Brian Orelli, PhDMar 3, 2020
TLRY building

Stock Market News: Tilray Comes Down; Thermo Fisher Makes a Big Buy

Dan CaplingerMar 3, 2020
dna-model-getty

Thermo Fisher Scientific to Spend $11.5 Billion Upgrading Its DNA Testing Game

Cory RenauerMar 3, 2020
Page 1

QGEN: Motley Fool Moneyball Superscore

69

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Qiagen

Qiagen N.V. is a leading global provider of sample to insight solutions that transform biological samples into molecular insights. The company specializes in sample technology consumables and instruments, serving the molecular diagnostics and life sciences sectors worldwide.

Products and Services
  • Nucleic acid stabilization and purification kits
  • Instruments for nucleic acid purification and quality control
  • Assays for oncology, infectious diseases, and genetic testing
Growth Outlook
  • Revenue of $535 million in Q2 2026, showing strong demand
  • Net income of $103 million in Q2 2026, reflecting profitability
  • Consistent investment in R&D to drive innovation and market expansion
Financial Highlights
  • Trailing twelve months (TTM) revenue of $2.1 billion, indicating robust performance
  • Net profit margin of 19.5% TTM, showcasing operational efficiency
  • Dividend yield of approximately 6.0%, appealing for income-focused investors
Qiagen N.V. has established itself as a key player in the healthcare sector, particularly in diagnostics and research. The company's diverse product offerings cater to a wide range of applications, from infectious disease testing to oncology. Recent financial performance highlights a strong revenue trajectory and profitability, supported by a solid net profit margin. The commitment to research and development positions Qiagen for continued growth and innovation in the rapidly evolving life sciences landscape. With a competitive dividend yield, the company may attract investors seeking both growth and income.
AI Generated • Aug 23, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

5,654

CEO

Thierry L. Bernard

Website

www.qiagen.com

Headquarters

Venlo, LI 5912 PL, NL

QGEN Financials

Key Financial Metrics (TTM)

Gross Margin

61.82%

Operating Margin

25.33%

Net Income Margin

19.49%

Return on Equity

11.60%

Return on Capital

9.58%

Return on Assets

6.95%

Earnings Yield

4.47%

Dividend Yield

0.79%

Payout Ratio

13.25%

Stock Overview

Market Cap

$9.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

206.07M

Volume

846.749

Avg. Volume

2.81M

Financials (TTM)

Gross Profit

$1.30B

Operating Income

$532.09M

EBITDA

$736.16M

Operating Cash Flow

$654.47M

Capital Expenditure

-$206.77M

Free Cash Flow

$447.70M

Cash & ST Invst.

$793.50M

Total Debt

$1.64B

Qiagen Performance Analysis

Qiagen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,141,518,000-4.9%
20232023-12-31USD 1,965,311,000-8.2%
20242024-12-31USD 1,978,214,0000.7%
20252025-12-31USD 2,089,999,0005.7%
Qiagen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.2%
Q42025-12-311.5%
Q12026-03-31-8.9%
Q22026-06-308.7%
Qiagen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.05-16.8%
20232023-12-31USD 1.65-19.5%
20242024-12-31USD 0.40-75.6%
20252025-12-31USD 2.04407.4%
Qiagen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3036.4%
Q42025-12-31-13.3%
Q12026-03-31-36.5%
Q22026-06-3051.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$535.04M

+0.3%

Gross Profit

$340.39M

+1.8%

Gross Margin

63.62%

N/A

Market Cap

$9.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.65M

N/A

Employees

5,500

N/A

Net Income

$103.40M

+7.4%

EBITDA

$142.13M

-22.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$793.50M

-16.8%

Total Debt

$1.64B

+13.8%

Accounts Receivable

$399.05M

+3.4%

Inventory

$311.36M

+6.4%

Long Term Debt

$1.63B

+83.9%

Short Term Debt

$16.52M

-97.0%

Return on Assets

6.95%

N/A

Return on Invested Capital

10.02%

N/A

Free Cash Flow

$157.76M

+30.8%

Operating Cash Flow

$200.69M

+24.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENSGThe Ensign Group, Inc.
$179.48-0.21%
HIMSHims & Hers Health, Inc.
$33.78+6.03%
TECHBio-Techne Corporation
$72.32+0.06%
ALGNAlign Technology, Inc.
$162.55+2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.60-0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.03+0.02%
IBITiShares Bitcoin Trust
$43.68+0.06%
MSTRStrategy
$119.25+0.06%

Questions About QGEN

What is the current price of Qiagen?

Qiagen is trading at $44.07 per share.

What is the 52-week range for Qiagen?

Over the past 52 weeks, Qiagen has traded between $32.53 and $57.82.

How much debt does Qiagen have?

As of the most recent reporting period, Qiagen reported total debt of $1.64B.

How much cash does Qiagen have on hand?

Qiagen reported $768.50M in cash and cash equivalents in its most recent financial results.

What is Qiagen’s dividend yield?

Qiagen currently has a dividend yield of 0.79%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services